Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Net Cash Flow data on record, last reported at $42.7 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 115.23% year-over-year to $42.7 million; the TTM value through Sep 2025 reached $22.3 million, up 118.02%, while the annual FY2024 figure was -$109.4 million, 193.5% down from the prior year.
  • Net Cash Flow reached $42.7 million in Q3 2025 per DNTH's latest filing, up from $3.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $197.4 million in Q1 2024 and bottomed at -$280.3 million in Q3 2024.
  • Average Net Cash Flow over 4 years is $3.2 million, with a median of -$10.9 million recorded in 2024.
  • The widest YoY moves for Net Cash Flow: up 2415.6% in 2024, down 339.72% in 2024.
  • A 4-year view of Net Cash Flow shows it stood at -$21.5 million in 2022, then fell by 15.99% to -$25.0 million in 2023, then surged by 56.41% to -$10.9 million in 2024, then surged by 492.38% to $42.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $42.7 million in Q3 2025, $3.1 million in Q2 2025, and -$12.7 million in Q1 2025.